Non-executive directors

Dr Rosie Benneyworth

Vice Chair

Dr Benneyworth works as a Portfolio GP in Somerset with a role representing GP providers for the Somerset Sustainability and Transformation Plan (STP). She is also a GP in and out of hours.

Rosie has previously held roles as the Managing Director of the South West Academic Health Science Network and a Clinical Commissioner for several years in Somerset.

Rosie was a NICE Fellow 2013-2016, and was a member of the group that developed the NICE guideline on Urinary Incontinence in Women. She is currently Vice Chair of NICE with board responsibility for the Technology Appraisal and Highly Specialised Technologies Appeals process.


Professor Martin Cowie

Non-Executive Director

Professor Martin Cowie is Professor of Cardiology at Imperial College and an Honorary Consultant Cardiologist at the Royal Brompton and Harefield NHS Foundation Trust.

Since 2003 he has been a clinical advisor for NICE on our acute and chronic heart failure guidelines, quality standards, commissioning guides, patient decision aids, and technology appraisals. In 2012 he became a NICE Specialty Advisor for cardiovascular interventions.

His major clinical and research interests are in health technology assessment and the delivery of efficient and effective care for patients with heart failure, focusing on new technologies: diagnostics, drugs or devices


Angela Coulter

Non-Executive Director

Professor Angela Coulter is a health policy analyst and researcher, with special interests in patient and public involvement. Her previous roles include Chief Executive of Picker Institute Europe, Director of Policy and Development at the King’s Fund, Director of the Health Services Research Unit at the University of Oxford and Director of Global Initiatives at the Informed Medical Decisions Foundation.

Angela has published more than 300 research papers and reports. She is the author of several books including The European Patient of the Future, winner of the 2004 Baxter Award. Her work has received awards from the Donabedian Foundation of Barcelona in 2012 and the International Shared Decision Making Conference in 2013.


Tom Wright

Non-Executive Director

Tom Wright CBE is Chief Executive of Age UK and is also chair of the Richmond Group of 14 leading health charities. Tom also sits on a range of health and social care bodies such as the Global Council on Brain Health.


Professor Sheena Asthana

Non-Executive Director

Professor Sheena Asthana is Professor of Health Policy at the University of Plymouth. Her research and teaching focus is on inequalities in health and health care, international public health and evidence-based public health.

She has worked with NICE to produce systematic reviews, evidence synthesis and economic analyses to inform our public health programme. Sheena brings experience of a wide variety of board appointments.


Tim Irish

Non-Executive Director

Tim has worked in the life sciences industry for 30 years. His career has spanned global health technology companies across Europe and North America, including GSK, GE and Philips.

Between 2007 and 2015 he served on 10 boards, 5 as chair, where he successfully executed 2 trade sales and raised significant equity financing, including an IPO. Tim’s current governance portfolio covers life sciences and healthcare and education, both public and private. This includes:

  • board roles as Non-Executive Director at NICE
  • various European MedTech Supervisory Board roles
  • Professor of Practice at King’s College London’s School of Management and Business.

Tim is currently NICE's Senior Independent Director.


Elaine Inglesby-Burke

Non-Executive Director

Elaine Inglesby-Burke has been a registered nurse since 1980. Her previous roles include being a nurse specialist manager at St Helens and Knowsley Hospital Trust and Director of Nursing at The Walton Centre in Liverpool. Most recently, Elaine was appointed Deputy Chief Executive at Salford Royal NHS Foundation Trust. She is also on the governing body at St Helens Clinical Commissioning Group and Willowbrook Hospice in St Helens.

Elaine has also played a significant role in national health campaigns, having been a member of the Prime Minister’s Nursing and Care Quality Forum. She was also involved with the Berwick National Advisory Group on the Safety of Patients in England, which is a group of healthcare experts that was set up to examine patient safety issues in the NHS.

Last year, Elaine was awarded a CBE on the Queen’s Birthday Honours List for her services to nursing.


Dr Rima Makarem

Non-Executive Director

Dr Rima Makarem has been Audit Chair in several NHS organisations, recently at NHS London and now at University College London Hospital. She is also the Chair for the National Travel Health Network and Centre (NaTHNaC), an Independent Council Member at St George’s University of London and a Board Trustee at Anchor Trust, a leading national provider of care homes and sheltered accommodation.

Rima has previously worked in the pharmaceutical industry in a number of roles including Director of Competitive Excellence at GlaxoSmithKline.


Industry representatives

Uday Bose

Industry representative

Uday Bose is currently Corporate Vice President, Head of Global Marketing, for Boehringer Ingelheim, Oncology. Based in Germany, he is responsible for all commercial aspects for the oncology portfolio spanning early development through to their marketed compounds.

Uday has extensive experience in the industry gained over 20 years. He started in health economics and has worked on NICE submissions and negotiations from his previous industry roles. The vast majority of his experience is with specialty products in oncology, osteoporosis and diseases of the CNS. In addition, he serves as Chair of Governors for his local infant and nursery school in West London.


Dr Mark Chakravarty

Industry representative

Mark holds a degree in Pharmacology and qualified in Medicine at the University of Manchester, UK, in 1995. He then held various hospital appointments in clinical medicine before taking a joint Medical Adviser post with the NHS Executive in the North West.

During this time Mark was the Chairman of the Northwest Junior Doctors Committee, member of the National Junior Doctors Executive Committee of the British Medical Association, and a national negotiator for Junior Doctors. He then studied business at Manchester Business School before joining Procter & Gamble, in 1999, as a Medical Advisor for Cardiology.

Mark held various roles of increasing seniority in Procter & Gamble from 1999 to 2017, including Head of Global Communications for Baby, Feminine & Family Care. Mark joined Novartis in 2017 as the Global Head of Communications and Patient Advocacy for Pharma.


Dr Mercia Page

Industry representative

Dr Page qualified in medicine from Kings College Hospital Medical School and spent 8 years in hospital practice in the NHS, before joining the pharmaceutical industry. She gained experience in clinical research and specialised in pharmaceutical medicine. She also completed an MBA from Ashridge in 2001.

Dr Page joined NICE in autumn 2003 as the Associate Director for the Guidelines Programme, and became the Director of the Centre for Clinical Practice. Mercia was a Director of Medical Affairs at MSD Ltd between April 2008 and March 2016. She was appointed to SMC as an industry member between 2009 and 2012. She is now a consultant pharmaceutical physician.


Dr David Gillen

Industry representative

Dr David Gillen (BSc MD FFPM) has been a member of the Appeal Committee since 2012. He is Medical Director for Celgene UK and Ireland. Prior to this role he was Head of International Medical Affairs for Gilead Sciences where he managed and led a group of Medical Directors across Europe and Asia-Pacific. Before this he was Vice President Medical Affairs for the Pfizer Primary Care Business Unit covering Europe, Canada, Australia and New Zealand where he established a regional medical affairs group covering Pfizer's primary care portfolio of medicines.

David qualified in Medicine from St Mary's Hospital in 1992. During his undergraduate medical training he completed a BSc in Physiology and Clinical Pharmacology. He retained this interest in Pharmaceutical Medicine during his postgraduate training in Medicine, Cardiology and General Practice and joined Pfizer Global Research and Development in Sandwich in 1998. At Pfizer, David has worked in R&D and in Medical Affairs for the UK and in New York for 4 years. David is passionate about and active in the UK Clinical Research community, most recently being part of the Academy of Medical Sciences working group looking into Streamlining UK Clinical Research Governance.

Beyond clinical research, David has served on the Innovation Sub-committee of the ABPI (Initiating the ABPI Real - World data project), has worked at NICE and the UKCRC and was a member of the RCP working party looking at the relationship between industry, academic medicine and the NHS.


Patrick Hopkinson

Industry representative

Patrick is Executive Director, World Wide Health Economics and Outcomes Research (WWHEOR) Markets at Bristol-Myers Squibb (BMS). He leads the team responsible for supporting country health technology assessment (HTA) submissions and access, for all countries outside of the US. He also leads WWHEOR HTA policy initiatives and is a member of the European Federation of Pharmaceutical Industries and Associations HTA Task force.

Before this role, Patrick led the BMS UK & Ireland Market Access function responsible for the HTA submissions to NICE, Scottish Medicines Consortium, All Wales Medicines Strategy Group and National Centre for Pharmacoeconomics. He also led the BMS HTA policy strategy with the Association of the British Pharmaceutical Industry. Previously Patrick worked at GSK for 14 years in Sales & Marketing, HEOR and Market Access.

Prior to GSK, Patrick worked as an oncology pharmacist for 8 years. He holds a Diploma in Clinical Pharmacy, a Masters in Health Economics and an MBA from Henley Management School.


Stuart Carroll

Industry representative

Stuart is a senior health economist and market access expert specialising in pharmaceuticals, health technology appraisal (HTA) and health policy. He holds a BA (Hons) in Politics and Economics (1st Class) from the University of Northumbria at Newcastle, an MSc in Health Economics (Distinction) from the University of York, and an MBA (Distinction) from the Imperial Business School. Stuart is currently the Head of Value & Access for Sanofi Pasteur (a company specialising in vaccines) and a member of the leadership team for UK & Ireland.

Prior to this, he was the Head of Market Access for UK & Ireland Biogen Idec in the UK & Ireland (a biotechnology company specialising in multiple sclerosis) having previously been the Head of Health Economics & Epidemiology in the UK for Sanofi Pasteur MSD (a leading pharmaceutical company specialising in vaccines) and having worked as a health economics consultant and policy adviser specialising in HTA, pricing and reimbursement and local market access pathways in the NHS.

Stuart has over 12 years of experience leading and managing multiple HTAs including for the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the All Wales Medicines Strategy Group (AWMSG) and the National Centre for Pharmacoeconomics (NCPE). As part of these HTA submissions, Stuart has been responsible for overseeing patient access schemes and the implementation of pricing agreements. He has also led and managed HTA and pricing submissions in Australia, New Zealand, Canada, Germany, France, Italy, Spain, Portugal, Sweden, Denmark, Norway, Finland and Eastern Europe, and has experience in leading national tenders for UK-wide vaccination programmes and liaising with the Joint Committee on Vaccination and Immunisation (JCVI). Stuart is a Fellow of the Royal Society of Public Health, a member of the New Drugs Committee (NDC) for the Scottish Medicines Consortium (SMC), and a Local Councillor for the Royal Borough of Windsor & Maidenhead where he is the Cabinet Member for Public Health & Communications.


David Tyas

Industry representative

David is the Associate Director for Health Economics and Outcomes Research (HEOR) at Bristol-Myers Squbb (BMS) UK & Ireland. David leads the BMS HEOR team and oversees all health economic activities and is accountable for ensuring scientifically robust evidence submission dossiers are prepared for all UK and Irish Health Technology Appraisal bodies.

David has been active in Health Technology Appraisals for over 10 years and previously held positions with other Association of the British Pharmaceutical Industry (ABPI) member companies: Lundbeck, Novartis, and AstraZeneca.

David currently represents BMS at ABPI for HTA related work streams and previously was a member of the NICE topic selection panel for mental health and a health economist industry representative on the New Medicines Group for the AWMSG.

David holds a PhD in Neurobiology from the University of Edinburgh and a Postgraduate diploma in Health Economics from the University of York.


Lay representatives

John Morris

Lay representative

John Morris has been a member of the Appeal Committee since 2011. Dr Morris's career began in pharmaceutical and crop protection scientific research. During this time he also developed an interest and expertise in psychodynamic counselling and interpersonal skills training. He then took these varied experiences and skills to the voluntary sector, managing information, support and advocacy services in two health charities, covering haemophilia and thrombosis and associated conditions such as hepatitis C and HIV.

Membership of another charity's advisory panel, the Long-term Medical Conditions Alliance and Patients in NICE gave him a broader understanding of the needs of people living with medical conditions. Having twice been a patient expert on hepatitis C NICE technology appraisals, he then joined the Royal College of Physicians to project manage the development of NICE clinical guidelines, primarily working on the COPD update. Most recently, he applied his ability of ‘translating' complex medical information into lay language to writing training materials on a host of healthcare subjects, and continues to support the UK's first gene therapy trial for haemophilia as its patient ombudsman.

He is passionate about empowering people to be self-managers of their health conditions and to participate fully in locally and national decision-making about NHS service provision. In particular, he is committed to ensuring the patient/carer voice is heard at all stages of the TA process.


Professor Alan Silman

Lay representative and appeal panel chair

Alan is an epidemiologist and rheumatologist. He is currently Professor of Musculoskeletal Health at Oxford University with specific interests in device epidemiology and in multimorbidity

From 2007 to 2014 Alan was Medical Director of Arthritis Research UK. In that post, he was responsible for providing the strategic direction and leadership to the charity’s research and education activities.  Prior to joining Arthritis Research UK, he was director of ARUK’s Epidemiology Unit in Manchester for 18 years.  Until the end of 2011, Alan was a consultant rheumatologist at the Manchester Royal Infirmary.

Some of his milestones include being elected as a Fellow of the Academy of Medical Sciences and awarded Honorary Doctorates from University of East Anglia in 2009 and from Keele University in 2012.  Alan is the UK editor of the main leading international textbook ‘Rheumatology’ (7th Edn Elsevier, Philadelphia).  He has published over 500 research papers and was listed amongst the world’s top 400 biomedical science researchers in 2013. 

His external responsibilities have included membership of the MHRA Pharmacovigilance Expert Advisory Group; Vice chair and then chair of the Epidemiological Assessment Panels of UK Universities Research Assessment Exercise (2002 and 2008); and Chairman, Ministry of Defence panel of research into the health of servicemen and women.  He chaired the NICE panel on local formularies 2012.


Colin Standfield

Lay representative

Colin Standfield has been a member of the Appeal Committee since 2011. Colin is an Oxford MA in English and has a background at Board level in advertising and marketing. He also has a long association with substance misuse issues and worked for 10 years as a Trustee and then Development Officer with Battling Addictions Together, a user-led Ealing charity helping people recover from drug and alcohol problems. He is a Trustee of Drugscope and has been involved with a number of Ealing and pan-London committees in the field, including the Ealing Drug and Alcohol Task Group and the Greater London Alcohol and Drug Alliance. He is Church Council Secretary and a former Senior Steward at Hanwell Methodist Church.

He is a skilled presenter and has experience of service improvement within the NHS; he has run redesign programmes for Substance Misuse and Mental Health teams in boroughs across the country. Colin was the elected Chair of the Ealing and West London Research Ethics Committee for over four years and was a Non-Executive Director of Ealing Primary Care Trust from 2004 to 2007.


Paddy Storrie

Lay representative and appeal panel chair

Paddy Storrie is a history graduate and has been involved as a lay member with NICE since 2004. His initial four years were as a member of the Citizens' Council, and between 2009 to 2014 as a lay member on Technology Appraisals Committee D. He sat in 2010 to 2011 on the Academy of Medical Science Working Group on the Regulation and Governance of Medical Research. 

Paddy has experience as a member of the MHRA Patient and Public Engagement Expert Advisory Group. He is on the Steering Committee of the High Intensity Specialist Led Acute Care research project, and has spoken twice at the Forum of Health Technology Appraisal International, a clearing house made up of representatives of regulators, payer bodies, and health technology businesses.

Outside education and health, he has been involved in long-term projects with Stonewall and The Soldiers' Charity.


NHS representatives

Dr Anthony Emmerson BSc MD FRCP FRCPCH

NHS representative

Consultant Neonatologist, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust.

Dr Anthony Emmerson has been a consultant neonatologist since 1993. In the recent past, as Clinical Lead for the Neonatal Network and Medical Director of the Neonatal Intensive Care Partnership, he was instrumental in delivering the Making it Better reconfiguration of obstetric, neonatal and paediatric services across Greater Manchester. He has sat on the NICE Interventional Procedures Advisory Committee since 2012 and was involved with developing the quality standards for Hypertension in Pregnancy. He is a clinical advisor for the Parliamentary and Health Service Ombudsman.

He has had a long standing interest in medical education and is Head of School of Paediatrics in the North Western Deanery. He has experience of appeals panels relating to training issues. He has research interests in neonatal care including vitamin D levels in newborn infants and is Medical Editor of the Journal Infant.


Kevin O'Shaughnessy

NHS representative

Kevin O’Shaughnessy has been a Consultant Clinical Pharmacologist since 1995. He studied Pharmacology before completing his medical training in Oxford with post-graduate training at the Hammersmith Hospital London.

He is currently an honorary Consultant Physician at Addenbrookes Hospital, Cambridge and a Reader in Clinical Pharmacology at the University of Cambridge. He also undertakes basic research into hypertension and has an active role in clinical pharmacology training for the East of England.


Dr Biba Stanton BMedSci (Hons) MBBS (Hons) MRCP PhD

NHS representative

Specialist registrar in Neurology at the Royal Free Hospital

Dr Biba Stanton is a specialist registrar in neurology at the Royal Free Hospital, with a clinical interest in behavioural neurology and functional disorders. She graduated in medicine from the University of Newcastle-Upon-Tyne in 2000 with distinction, having also been awarded first class honours in her intercalated Bachelor of Medical Science degree.

She was awarded a PhD in psychology from King’s College London in 2009, and has research experience in epidemiology, clinical trials, neuropsychology and neuro-imaging. She chaired the Association of British Neurologists (ABN) trainees’ committee from 2009-2013, also serving on ABN Council, the ABN meetings committee, the Joint Clinical Neurosciences committee of the Royal College of Physicians and the neurology Specialty Advisory Committee. She works part time, spending two days per week looking after her 3 young sons, and is also a Governor of Rosendale Primary School.


Dr Ashutosh Wechalekar MD, FRCP, FRCPath, DM,

NHS representative

UK National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Campus, London, UK

Ashutosh Wechalekar is a Senior Lecturer and Honorary Consultant Haematologist at University College London Medical School and the Royal Free London NHS Foundation Trust.

He trained in haematology in the UK and Canada. In 2004, he joined the UK National Amyloidosis Centre funded by a grant from Leukaemia research fund and is a consultant at the centre since 2007. He is a board member of UK Myeloma forum. He has been key in establishing the UK amyloidosis network and represents the network as a stakeholder in various forums. He is a member of the British Society haematology guidelines group for developing guidelines for treatment of multiple myeloma and AL amyloidosis.

His clinical research has clarified the role of drugs like bortezomib in the treatment pathway for amyloidosis. His academic interests are focused on biomarkers in cardiac amyloidosis, novel imaging methods for the heart in all types of amyloidosis, characterization and treatment of systemic AL amyloidosis as well as multiple myeloma including clinical trials of new and novel agents in these disorders. He has published extensively in these areas.